Is Peptide Receptor Radionuclide Therapy Effective in the Treatment of Radioactive Iodine-Refractory Differentiated Thyroid Cancer?—A Case Report

Read full text Summarise with VIRAT
Authors: A Çelik, Tarık Şengöz
Cited by: 0
References: 10

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Radioiodine-refractory differentiated thyroid cancer (RAIR-DTC) represents a major clinical challenge due to its limited response to conventional treatment and poor prognosis. Peptide receptor radionuclide therapy (PRRT) has emerged as a promising treatment modality in patients with somatostatin receptor (SSTR)-positive tumors. We present an 82-year-old female patient with RAIR-DTC who underwent six cycles of PRRT after demonstrating SSTR positivity on Ga-68 DOTATATE positron emission tomography/computed tomography. This case highlights the limited therapeutic efficacy of PRRT in RAIR-DTC, despite favorable imaging characteristics. It underscores the need for better patient selection and further research to clarify the role of PRRT in this population.

Fields of Study & Subjects

Thyroid Cancer Diagnosis and Treatment Radiopharmaceutical Chemistry and Applications Neuroendocrine Tumor Research Advances

Publication details

Journal / source
Nigerian Journal of Clinical Practice
Volume
29
Issue
3
Pages
360–363
Publication date
1 March 2026
Language
EN